PRMS Antibody

Introduction to PRMS Antibody

PRMS antibodies (Premembrane-specific antibodies) are a class of immunoglobulins that target the premembrane (prM) protein of flaviviruses, including dengue virus (DENV), Zika virus (ZIKV), and others. These antibodies play a dual role in viral infections: they can neutralize immature virions but also contribute to antibody-dependent enhancement (ADE) of disease severity . The prM protein is a structural component critical for virion maturation, and its incomplete cleavage during viral assembly results in partially mature particles that retain prM on their surface . PRMS antibodies primarily recognize these prM-retaining virions, making them key players in both protective immunity and pathogenic outcomes.

Antibody Structure

• Fab Region: Binds to prM epitopes on partially mature virions. Epitope mapping reveals recognition of a single major antigenic site on prM, with minor variations in binding modes .

• Fc Region: Mediates interactions with Fcγ receptors on immune cells, driving ADE in secondary infections .

Key Functional Roles

Epitope Specificity and Neutralization

• PRMS antibodies recognize a conserved antigenic site on prM, with residues K26 and E28 being critical for binding .

• Neutralization efficiency depends on virion maturation state:

  • Immature virions (prM⁺): Highly susceptible to neutralization .

  • Mature virions: Resistant to neutralization due to prM cleavage .

Pathogenic Role in Dengue Infections

• In vitro Studies: PRMS antibodies enhance DENV infection in Fcγ receptor-bearing cells (e.g., monocytes) by up to 70% .

• In vivo Models:

  • Passive transfer of intact PRMS antibodies in mice increases viral load in serum, liver, and spleen, leading to lethal outcomes .

  • Fc-modified PRMS antibodies (incapable of Fcγ binding) protect against DENV-induced lethality, confirming the role of ADE in pathogenesis .

Diagnostic Utility

• PRMS antibodies serve as serocomplex-specific markers, distinguishing between flavivirus infections (e.g., DENV vs. ZIKV) .

• Western blot assays detect prM-specific antibodies to differentiate primary and secondary infections .

Therapeutic Challenges

• Vaccine Design: PRMS antibodies complicate vaccine development due to their dual neutralization/ADE effects .

• Drug Development: Fc-engineered PRMS antibodies show promise in blocking ADE while retaining neutralization capacity .

Future Directions

• Precision Epitope Mapping: Define prM conformational epitopes to design ADE-resistant vaccines .

• Cross-Reactivity Studies: Investigate PRMS antibody interactions with emerging flaviviruses (e.g., Omicron VoC) .

• Therapeutic Antibodies: Optimize Fc engineering to maximize neutralization while minimizing ADE .